AVESTHAGEN LIMITED
Renuka Jain currently serves as the Senior Vice President at Avesthagen Limited, a position held since May 2020, after previously working as Vice President of New Products at Sami Labs Limited from January 2018 to April 2020. Prior to that, Renuka held the role of Chief Scientific Officer for bioNutrition and Metabolomics at Avesthagen from August 2007 to December 2017, focusing on the development of novel plant bioactives for various metabolic disorders. Academic experience includes a postdoctoral fellowship in Biochemistry at the University of Missouri, where research centered on proteome profiling, and another postdoctoral role at Umea Plant Science Centre in Sweden studying mitochondrial proteome adaptation. Renuka's early research at Avestha Gengraine Technologies emphasized proteomics studies on Indian medicinal plants, with additional research experience at the Bhabha Atomic Research Centre. Educational credentials include a PhD in Botany/Plant Biology, an M.Phil. in Botany/Plant Physiology, and an MSc in Botany/Plant Biology, all from Jiwaji University.
This person is not in any teams
AVESTHAGEN LIMITED
Avesthagen Limited - Brief Summary Avesthagen is a leading systems biology life science company uniquely positioned to help solve some of the world’s biggest healthcare and environmental challenges. Since its inception 20 years ago, Avesthagen has introduced new ideas, technologies, and products, for the life sciences market. The Avestagenome Project® is Avesthagen’s largest epidemiological study ever conducted in India, and the first such detailed system biology study worldwide on an endogamous population. The project has collected a biobank of Parsi blood samples with extensive patient data from 4,500 members and investigates the molecular basis of longevity and age-related disorders, prioritizing cancers, cardiovascular disease, diabetes and neurological disorders. Recognizing the importance of the Parsi cohort and the unique systems’ biology approach to research, the U.S.-based Foundation for a Smoke-Free World, whose mission is to end smoking within this generation, recently awarded a grant to Avesthagen Limited® to prioritize research into lung and tobacco-related cancers. Avesthagen will combine liquid biopsy, next-generation sequencing (NGS), state- of-the-art bioinformatics, artificial intelligence and machine learning to identify predictive and early-stage biomarkers of cancers in smokers. The project will use non-Parsi smoker and non-smoker samples from the wider Indian and other populations to gain further insights into the evidence behind such data. Avesthagen is expected to be a key player in the lucrative personalised medicine market, which is projected to reach a value of US $1.7 trillion by 2026. Today, Avesthagen is proud to build on this heritage by partnering with others to tackle unprecedented challenges now facing our world. We believe we can provide enough healthy food for people everywhere and protect the environment for generations to come.